Application of glutathione peroxidase 3 as therapeutic target in preparation of pulmonary fibrosis drugs

By using GPX3 as a therapeutic target and employing Ebselen nebulized inhalation formulation, which acts directly on the lungs, the limitations of IPF treatment options are addressed, achieving effective intervention and potential therapeutic effects on the oxidative stress pathway.

CN121891533APending Publication Date: 2026-04-21CHIMEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511936325.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-22
Publication Date
2026-04-21

AI Technical Summary

Technical Problem

Existing technologies offer limited and ineffective treatment options for idiopathic pulmonary fibrosis (IPF). Oxidative stress plays a key role in its pathogenesis, and there is a lack of effective treatment strategies targeting oxidative stress pathways.

Method used

Using glutathione peroxidase 3 (GPX3) as a therapeutic target, its agonist Ebselen is administered via nebulized inhalation. Inhalation formulations such as nebulized inhalation liquids, dry powder inhalers, or aerosols are prepared to act directly on the lungs and inhibit oxidative stress pathways.

Benefits of technology

It provides a novel biological target with a clearly defined mechanism of action, directly targeting the core pathological aspects of pulmonary fibrosis, which may have better efficacy and curative potential, and simplifies the drug development process.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of glutathione peroxidase 3 as a therapeutic target in preparation of a medicine for treating pulmonary fibrosis, and an application of a compound Ebselen in preparation of a medicine for treating pulmonary fibrosis. Through single cell and space transcriptomics analysis, it is found for the first time that expression of GPX3 in pulmonary fibrosis patients and model animal lung tissues is significantly reduced. In-vivo and in-vitro experiments prove that up-regulation of GPX3 expression can effectively inhibit fibroblast activation, migration, proliferation and oxidative stress and block a TGF-beta1 / Smad signal channel, so that collagen deposition and pulmonary fibrosis pathological change are relieved. Furthermore, a GPX3 simulant Ebselen is given by adopting an aerosol inhalation mode, is preferably loaded in liposome, and shows a remarkable anti-fibrosis effect in two mouse pulmonary fibrosis models induced by bleomycin and silicon dioxide. The invention provides a brand-new therapeutic target and a medicine scheme with clinical transformation potential for pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art